Efficacy, safety and prognostic factors of Capecitabine plus Temozolomide regimen in patients with thymic neuroendocrine neoplasms

#4006

Introduction: Thymic neuroendocrine neoplasms (T-NENs) are rare mediastinal malignancies that lack established treatment guidelines. While the Capecitabine and Temozolomide (CapTem) regimen has demonstrated significant efficacy in patients with pancreatic NENs, its applicability and effectiveness in treating T-NENs remain underexplored.

Aim(s): This study seeks to investigate the efficacy, safety, and prognostic factors associated with the CapTem regimen in T-NEN patients.

Materials and methods: Thirty-eight T-NEN patients treated with CapTem at our center were analyzed. We assessed the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse effects. We also examined patients' clinicopathological characteristics and their correlations with CapTem efficacy.

Conference:

Presenting Author: Liu M

Authors: Liu M, Yan X, Lin X, Chen L, Wang Y,

Keywords: Capecitabine plus Temozolomide, Thymic Neuroendocrine Neoplasm, CapTem, T-NEN,